Kintara Therapeutics Files 8-K
Ticker: HURA · Form: 8-K · Filed: Jul 12, 2024 · CIK: 1498382
Sentiment: neutral
Topics: corporate-filing, financials, amendment
Related Tickers: KTRA
TL;DR
KINTARA files 8-K with corporate updates and financials.
AI Summary
Kintara Therapeutics, Inc. filed an 8-K on July 12, 2024, reporting amendments to its articles of incorporation or bylaws and financial statements. The company, formerly known as DelMar Pharmaceuticals, Inc. and Berry Only Inc., is incorporated in Nevada and has its principal executive offices in San Diego, California.
Why It Matters
This filing indicates corporate updates and the submission of financial statements, which are crucial for investors to understand the company's current status and financial health.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not contain information that inherently increases risk.
Key Players & Entities
- Kintara Therapeutics, Inc. (company) — Registrant
- DelMar Pharmaceuticals, Inc. (company) — Former company name
- Berry Only Inc. (company) — Former company name
- July 12, 2024 (date) — Date of report
- Nevada (jurisdiction) — State of incorporation
- San Diego, California (location) — Principal executive offices
FAQ
What specific amendments were made to Kintara Therapeutics' articles of incorporation or bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in the provided text.
When was Kintara Therapeutics, Inc. incorporated?
The filing states that Kintara Therapeutics, Inc. is incorporated in Nevada.
What is the principal executive office address for Kintara Therapeutics, Inc.?
The principal executive offices are located at 9920 Pacific Heights Blvd, Suite 150, San Diego, California, 92121.
What were Kintara Therapeutics' former company names?
Kintara Therapeutics, Inc. was formerly known as DelMar Pharmaceuticals, Inc. and Berry Only Inc.
What is the filing date of this 8-K report?
The report was filed on July 12, 2024.
Filing Stats: 600 words · 2 min read · ~2 pages · Grade level 12.8 · Accepted 2024-07-12 17:17:26
Filing Documents
- ktra-20240712.htm (8-K) — 41KB
- ktra-ex3_1.htm (EX-3.1) — 1KB
- ktra-ex3_2.htm (EX-3.2) — 1KB
- img51280976_0.jpg (GRAPHIC) — 451KB
- img52204497_0.jpg (GRAPHIC) — 583KB
- 0000950170-24-083280.txt ( ) — 1582KB
- ktra-20240712.xsd (EX-101.SCH) — 25KB
- ktra-20240712_htm.xml (XML) — 5KB
03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. Kintara Therapeutics, Inc. (the " Company ") previously designated (a) 5,000,000 shares of preferred stock as Special Voting Preferred Stock (the " Special Voting Preferred Stock ") and (b) 1,000,000 shares of preferred stock as Series B Preferred Stock (the " Series B Preferred Stock "). The Company filed Withdrawals of Designation relating to the Special Voting Preferred Stock and the Series B Preferred Stock with the Secretary of State of Nevada and terminated the designation of its Special Voting Preferred Stock on July 12, 2024 and Series B Preferred Stock on July 12, 2024. At the time of the filing of the Withdrawals of Designation, no shares of any of the previously designated Special Voting Preferred Stock and Series B Preferred Stock were outstanding. The Withdrawals of Designation were effective upon filing, and eliminated from the Company's Articles of Incorporation all matters set forth in the previously-filed Certificates of Designation with respect to the previously designated Special Voting Preferred Stock and Series B Preferred Stock.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 3.1 Certificate, Amendment or Withdrawal of Designation, relating to the Special Voting Preferred Stock, filed with the Secretary of State of Nevada on July 12, 2024 3.2 Certificate, Amendment or Withdrawal of Designation, relating to the Series B Preferred Stock, filed with the Secretary of State of Nevada on July 12, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KINTARA THERAPEUTICS, INC. Date: July 12, 2024 By: /s/ Robert E. Hoffman Name: Robert E. Hoffman Title: Chief Executive Officer